Ameliorative role of rosiglitazone in hyperhomocysteinemia-induced experimental cardiac hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 1, 2010, Pages 53-59

  Singh, Amrit Pal ^a,b   Kaur, Tajpreet ^a   Dahiya, Randhir Singh ^a   Singh, Nirmal ^a   Singh Bedi, Preet Mohinder ^b  

^a PUNJABI UNIVERSITY   (India)

^b GURU NANAK DEV UNIVERSITY   (India)

Author keywords

cardiac hypertrophy; hyperhomocysteinemia; rosiglitazone

Indexed keywords

COLLAGEN; GLUTATHIONE; HOMOCYSTEINE; METHIONINE; ROSIGLITAZONE; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CONTROLLED STUDY; DRUG MEGADOSE; HEART; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; HYPERHOMOCYSTEINEMIA; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; BLOOD; BLOOD PRESSURE; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; HYPERTROPHY, LEFT VENTRICULAR; MALE; METHIONINE; OXIDATIVE STRESS; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 77955226925     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181de308b     Document Type: Article

References (38)

1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-341.
2. Balakumar P, Singh AP, Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods. 2007;56:1-10.
3. Balakumar P, Singh AP, Ganti SS, et al. Hyperhomocysteinemia and cardiovascular disorders: is there a correlation? Trends Med Res. 2007;2: 160-166.
4. Joseph J, Joseph L, Shekhawat NS, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol. 2003;285:H679-H686.
5. Singh AP, Singh M, Balakumar P. Effect of mast cell stabilizers in hyperhomo-cysteinemia-induced cardiac hypertrophy in rats. J Cardiovasc Pharmacol. 2008;51:596-604.
6. Herrmann M, Taban-Shomal O, Hübner U, et al. A review of homocysteine and heart failure. Eur J Heart Fail. 2006;8:571-576.
7. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferatoractivated receptor agonists. Diabetes. 2005;54:2460-2470. (Pubitemid 41134276)
8. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor- gamma agonist in hypercholesterolemia. Circulation. 2003;108: 2805-2811.
9. Yue Tl TL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2001;104:2588-2594.
10. Bolten CW, Payne MA, McDonald WG, et al. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. Diab Vasc Dis Res. 2007;4:117-123.
11. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105:1240-1246.
12. Rose M, Balakumar P, Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology. 2007;80:177-184.
13. Murthy SN, Obregon DF, Chattergoon NN, et al. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism. 2005;54:645-652.
14. Simko F, Pelouch V, Kyselovic J. Captopril fails to reverse hypertrophy of the left ventricle induced by aortic insufficiency. Physiol Res. 2002;51: 27-33.
15. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thio-barbituric acid reaction. Anal Biochem. 1979;95:351-358.
16. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with folin-phenol reagent. J Biol Chem. 1951;193:265-275.
17. Wang HD, Pagano PJ, Du Y, et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res. 1998;82:810-818.
18. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882-888.
19. Mori T, Chen YF, Feng JA, et al. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res. 2004;61:771-779.
20. Dolber PC, Spach MS. Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment. Stain Technol. 1987;62: 23-26.
21. Shinzato T, Ohya Y, Nakamoto M, et al. Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats. Hypertens Res. 2007;30:863-873.
22. Tyagi N, Sedoris KC, Steed M, et al. Mechanisms of homocysteineinduced oxidative stress. Am J Physiol Heart Circ Physiol. 2005;289: H2649-H2656.
23. Zhang X, Li H, Jin H, et al. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol. 2000;279:F671-F678.
24. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis. 1997;132: 177-185.
25. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardio-vascular system. Br J Pharmacol. 2000;129:823-834.
26. Kelly DP. PPARs of the heart: three is a crowd. Circ Res. 2003;92: 482-484.
27. Bonaventura D, Tirapelli CR, Haddad R, et al. Chronic methionine loadinduced hyperhomocysteinemia enhances rat carotid responsiveness for angiotensin II. Pharmacology. 2004;70:91-99.
28. Danser AH, Saris JJ, Schuijt MP, et al. Is there a local renin-angiotensin system in the heart? Cardiovasc Res. 1999;44:252-265.
29. Kassab S, Garadah T, Abu-Hijleh M, et al. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats. J Renin Angiotensin Aldosterone Syst. 2006;7:206-211.
30. Ren L, Li Y, Li Y, et al. The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in dietinduced hypercholesterolemic rats. Cell Biochem Funct. 2010;28:58-65.
31. Bao Y, Li R, Jiang J, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem. 2008;317: 189-196.
32. Golbahar J, Aminzadeh MA, Kassab SE, et al. Hyperhomocysteinemia induces insulin resistance in male Sprague-Dawley rats. Diabetes Res Clin Pract. 2007;76:1-5.
33. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248.
34. Ungvari Z, Csiszar A, Edwards JG, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2003;23:418-424.
35. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
36. Sugden PH, Clerk A. Regulation of mitogen-activated protein kinase cascades in the heart. Adv Enzyme Regul. 1998;38:87-98.
37. Bai YP, Liu YH, Chen J, et al. Rosiglitazone attenuates NF-kappaBdependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem Biophys Res Commun. 2007;360:20-26.
38. Blasi ER, Heyen J, Hemkens M, et al. Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy Sprague-Dawley rats. PPAR Res. 2009.